View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Novo Nordisk Pharmatech to Attend ESACT

Novo Nordisk Pharmatech has announced it will be attending the 25th European Society for Animal Cell Technology (ESACT) meeting.

The event will be held from 14 May to 17 May in Lausanne, Switzerland. This years’ ESACT programme is designed to provide access to the latest innovation and advances in animal cell technology.

The event will be hosted in the Swiss Tech Convention Centre and Novo Nordisk Pharmatech will be sponsoring the event. The company invites you to visit its stall at booth #65-66.

Novo Nordisk Pharmatech is one of the leading worldwide suppliers of recombinant insulin. Its products are key components in serum-free growth media for mammalian cells and approved by regulatory bodies worldwide, including the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its products are also manufactured to current good manufacturing practice (cGMP) standards, guaranteeing:

  • Global regulatory compliance
  • Consistent high quality
  • Extensive regulatory documentation
  • Continuous availability
  • Secure global supply chain
  • High levels of service and support

Novo Nordisk Pharmatech delivers a proven record of product purity, reliability, and consistency. It can even tailor quality products for future therapies.

For more than 30 years, the National Research Council of Canada has been helping clients develop, optimise, scale-up and transfer bioprocesses to produce biologics and...
The Chinese hamster ovary (CHO) cell line is widely used for the production of recombinant proteins due to its high growth capacity and productivity, as...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology